CTLA4 and neoplasm: Peritumoral delivery of PIGF2-PDL1 or PIGF2-CTLA4 led to increased tumor retention and decreased plasma concentration (p < 0.01) of these antibodies compared to intraperitoneal or peritumoral administration of unconjugated antibodies [132].